陽普醫療(300030.SZ):陽普智慧醫療擬吸收合併全資子公司廣州惠僑
格隆匯10月12日丨陽普醫療(300030.SZ)公佈,公司第五屆董事會第十二次會議和第五屆監事會第十次會議審議通過了《關於全資子公司之間吸收合併的議案》。根據中共中央、國務院印發的《橫琴粵澳深度合作區建設總體方案》,結合當前國內醫改政策,為提前佈局公司業務,立足全球視角,踐行公司整合計劃,有效進行資源整合,加強顧客粘性,同時優化公司管理結構,提高運營效率,激發公司可持續的長期發展活力,全資子公司陽普智慧醫療科技(廣東)有限公司(“陽普智慧醫療”)擬吸收合併全資子公司廣州惠僑計算機科技有限公司(“廣州惠僑”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.